Beth Wittmer, RN, OCN, senior manager of care management at Florida Cancer Specialists, addresses how nurses are being educated about biosimilars.
Transcript:
What are practices doing to prepare for the arrival of anticancer biosimilars, and how are nurses in particular being educated?
Well from our practice, we have a very large pharmacy, our own in-house pharmacy Rx to Go. They are preparing by meeting with the pharmaceutical companies and trying to find the best options payable as well as delivering the drug.
Then we work with the pharmacists there who give us education. For our care management department, we rolled that out in webinars to our nurses so that they’re well aware of the side effects and how to manage the patient.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.